Retrospective Study
Copyright ©The Author(s) 2021.
World J Clin Cases. Oct 26, 2021; 9(30): 9011-9022
Published online Oct 26, 2021. doi: 10.12998/wjcc.v9.i30.9011
Table 1 Patient demographics and clinical characteristics
Variable
Primary cohort
Validation cohort
n
%
n
%
Gender
Female6335.22633.8
Male11664.85166.2
Age, yr
≤ 607441.33241.6
> 6010558.74558.4
Smoking history
No12268.25976.6
Yes5731.81823.4
Drinking history
No13474.96483.1
Yes4525.11316.9
Tumor location
Upper2312.9810.4
Middle11162.04659.7
Lower4525.12329.9
Histology
Pure PSCE10659.25774.1
Mixed PSCE7340.82025.9
T stage
T1a/T1b3419.01924.7
T26335.23140.2
T3/T48245.82735.1
N stage
N08748.63545.4
N16435.83039.0
N2/N32815.61215.6
Metastasis
No13675.96077.9
Yes4324.11722.1
Treatment methods
Surgery15586.66888.3
Others2413.4911.7
CD56
Negative4525.11519.5
Positive12474.96280.5
Syn
Negative4022.41722.1
Positive13977.66077.9
CgA
Negative11262.64761.1
Positive6737.43038.9
Table 2 Concordance index of nomogram model and tumor node metastasis stage for overall survival prediction in the primary and validation cohorts
VariablePrimary cohort
Validation cohort

C-index (95%CI)
P value
C-index (95%CI)
P value
Nomogram model0.659 (0.607-0.712)0.0330.700 (0.622-0.778)0.041
7th TNM staging0.591 (0.517-0.666)0.605 (0.490-0.721)
Table 3 Cox regression analysis for groups based on the model in the primary cohort
Groups
OS mean
1-yr (%)
3-yr (%)
5-yr (%)
Sig
HR (95%CI)
Low risk71.783.457.533.4--
Medium risk19.866.431.721.40.0041.93 (1.23-3.03)
High risk10.0334.84.4-0.0005.47 (3.08-9.73)